脂蛋白与心血管疾病残余风险的研究现状
Research Status of Lipoprotein and Residual Risk of Cardiovascular Disease
摘要: 尽管心血管疾病的防治取得了较为突出的成果，但其患病率和病死率仍较高。目前的指南针对降低低密度脂蛋白胆固醇(LDL-C)浓度，以减少动脉粥样硬化性心血管疾病(ASCVD)风险，尽管积极降低LDL-C，但残留ASCVD风险仍然存在，因此积极预防及治疗心血管疾病迫在眉睫，寻求新的方法降低心血管疾病的残余风险具有重要临床意义。本文主要总结了脂蛋白(LDL-C, HDL-C, TG, RLPs, Lp(a))与心血管疾病残余风险有关的证据。
Abstract: Although the prevention and treatment of cardiovascular diseases have made remarkable achievements, the prevalence and mortality of cardiovascular diseases are still high. Current guide-lines aim to reduce the concentration of low-density lipoprotein cholesterol (LDL-C) to reduce the risk of atherosclerotic cardiovascular disease (ASCVD). Despite aggressive lowering of LDL-C, the risk of residual ASCVD remains, making active prevention and treatment of cardiovascular disease urgent. It is of great clinical significance to seek new methods to reduce the residual risk of cardio-vascular disease. This review summarizes the evidence that lipoproteins (LDL-C, HDL-C, TG, RLPs, Lp(a)) are associated with residual risk of cardiovascular disease.
文章引用：吴美霞, 李蓉. 脂蛋白与心血管疾病残余风险的研究现状[J]. 临床医学进展, 2023, 13(6): 9211-9216. https://doi.org/10.12677/ACM.2023.1361290

参考文献

[1] Arnett, D.K., Blumenthal, R.S., Albert, M.A., et al. (2019) 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Associa-tion Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 74, 1376-1414. [Google Scholar] [CrossRef] [PubMed]
[2] Jacobson, T.A., Ito, M.K., Maki, K.C., et al. (2015) National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report. Journal of Clin-ical Lipidology, 9, 129-169. [Google Scholar] [CrossRef] [PubMed]
[3] Khetarpal, S.A. and Rader, D.J. (2015) Triglyceride-Rich Lipopro-teins and Coronary Artery Disease Risk: New Insights from Human Genetics. Arteriosclerosis, Thrombosis, and Vas-cular Biology, 35, e3-e9. [Google Scholar] [CrossRef] 
[4] Grundy, S.M., Stone, N.J., Bailey, A.L., Beam, C., Birtcher, K.K., Blumenthal, R.S., et al. (2019) 2018 AHA/ACC/ AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cho-lesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 73, e285-e350. [Google Scholar] [CrossRef] [PubMed]
[5] Mach, F., Baigent, C., et al. (2019) 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk: The Task Force for the Man-agement of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal, 41, 111-188.
[6] Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., et al. (2010) Efficacy and Safety of More Intensive Lowering of LDL Cholesterol: A Meta-Analysis of Data from 170,000 Participants in 26 Randomised Trials. Lancet, 376, 1670-1681. [Google Scholar] [CrossRef] 
[7] Cannon, C.P., Blazing, M.A., Giugliano, R.P., McCagg, A., White, J.A., Theroux, P., et al. (2015) Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. The New England Journal of Medicine, 372, 2387-2397. [Google Scholar] [CrossRef] 
[8] Sabatine, M.S., Giugliano, R.P., Keech, A.C., Honarpour, N., Wiv-iott, S.D., Murphy, S.A., et al. (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England Journal of Medicine, 376, 1713-1722. [Google Scholar] [CrossRef] 
[9] Maki, K.C. (2018) The ODYSSEY Outcomes Trial: Clinical Impli-cations and Exploration of the Limits of What Can Be Achieved through Lipid Lowering. Journal of Clinical Lipidology, 12, 1102-1105. [Google Scholar] [CrossRef] [PubMed]
[10] Abifadel, M., Varret, M., Rabès, J.P., Allard, D., Ouguerram, K., Devillers, M., et al. (2003) Mutations in PCSK9 Cause Autosomal Dominant Hypercholesterolemia. Nature Genetics, 34, 154-156. [Google Scholar] [CrossRef] [PubMed]
[11] Cohen, J.C., Boerwinkle, E., Mosley, T.H. and Hobbs, H.H. (2006) Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. The New England Journal of Medicine, 354, 1264-1272. [Google Scholar] [CrossRef] 
[12] Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., Raal, F.J., Blom, D.J., Robinson, J., et al. (2015) Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. The New England Journal of Medicine, 372, 1500-1509. [Google Scholar] [CrossRef] 
[13] Toth, P.P., Barter, P.J., Rosenson, R.S., Boden, W.E., Chapman, M.J., Cuchel, M., et al. (2013) High-Density Lipoproteins: A Consensus Statement from the National Lipid Association. Journal of Clinical Lipidology, 7, 484-525. [Google Scholar] [CrossRef] [PubMed]
[14] Di Angelantonio, E., Sarwar, N., Perry, P., et al. (2009) Major Li-pids, Apolipoproteins, and Risk of Vascular Disease. JAMA, 302, 1993-2000. [Google Scholar] [CrossRef] [PubMed]
[15] Voight, B.F., Peloso, G.M., Orho-Melander, M., et al. (2012) Plasma HDL Cholesterol and Risk of Myocardial Infarction: A Mendelian Randomisation Study. Lancet, 380, 572-580. [Google Scholar] [CrossRef] 
[16] Boden, W.E., Probstfield, J.L., Anderson, T., et al. (2011) Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. The New England Journal of Medicine, 365, 2255-2267. [Google Scholar] [CrossRef] 
[17] Schwartz, G.G., Olsson, A.G., Abt, M., et al. (2012) Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. The New England Journal of Medicine, 367, 2089-2099. [Google Scholar] [CrossRef] 
[18] Madsen, C.M., Varbo, A. and Nordestgaard, B.G. (2017) Extreme High High-Density Lipoprotein Cholesterol Is Paradoxically Associated with High Mortality in Men and Women: Two Prospective Cohort Studies. European Heart Journal, 38, 2478-2486. [Google Scholar] [CrossRef] [PubMed]
[19] Rohatgi, A., Westerterp, M., von Eckardstein, A., et al. (2021) HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research. Circulation, 143, 2293-2309. [Google Scholar] [CrossRef] 
[20] Yu, K.C. and Cooper, A.D. (2001) Postprandial Lipoproteins and Atherosclerosis. Frontiers in Bioscience, 6, 332-354. [Google Scholar] [CrossRef] 
[21] Balling, M., Afzal, S., Varbo, A., Langsted, A., Smith, G.D. and Nordestgaard, B.G. (2020) VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated with apoB-Containing Lipoproteins. Journal of the American College of Cardiology, 76, 2725-2735. [Google Scholar] [CrossRef] [PubMed]
[22] Joshi, P.H., Khokhar, A.A., Massaro, J.M., Lirette, S.T., Griswold, M.E., Martin, S.S., et al. (2016) Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. Journal of the American Heart Association, 5, e002765. [Google Scholar] [CrossRef] 
[23] Elshazly, M.B., Mani, P., Nissen, S., et al. (2020) Remnant Cho-lesterol, Coronary Atheroma Progression and Clinical Events in Statintreated Patients with Coronary Artery Disease. European Journal of Preventive Cardiology, 27, 1091-1100. [Google Scholar] [CrossRef] [PubMed]
[24] Lin, A., Nerlekar, N., Rajagopalan, A., et al. (2019) Remnant Cholesterol and Coronary Atherosclerotic Plaque Burden As-sessed by Computed Tomography Coronary Angiography. Atherosclerosis, 284, 24-30. [Google Scholar] [CrossRef] [PubMed]
[25] Schwartz, G.G., Abt, M., Bao, W., et al. (2015) Fasting Triglycerides Predict Recurrent Ischemic Events in Patients with Acute Coronary Syndrome Treated with Statins. Journal of the American College of Cardiology, 65, 2267-2275. [Google Scholar] [CrossRef] [PubMed]
[26] Faergeman, O., Holme, I., Fayyad, R., et al. (2009) Plasma Tri-glycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering Trials of Statins in Patients with Coronary Artery Disease. The American Journal of Cardi-ology, 104, 459-463. [Google Scholar] [CrossRef] [PubMed]
[27] Vallejo-Vaz, A.J., Fayyad, R., Boekholdt, S.M., et al. (2018) Triglyceride Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events among Patients Receiving Statin Therapy in the TNT Trial. Circulation, 138, 770-781. [Google Scholar] [CrossRef] 
[28] Khera, A.V., Won, H.H., Peloso, G.M., et al. (2017) Association of Rare and Common Variation in the Lipoprotein Lipase Gene with Coronary Artery Disease. JAMA, 317, 937-946. [Google Scholar] [CrossRef] [PubMed]
[29] Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar, N., Sandhu, M.S., Ricketts, S.L., et al. (2010) Triglyceride-Mediated Pathways and Coronary Disease: Collaborative Analysis of 101 Studies. Lancet, 375, 1634-1639. [Google Scholar] [CrossRef] 
[30] Deloukas, P., Kanoni, S., Willenborg, C., Farrall, M., As-simes, T.L., Thompson, J.R., et al. (2013) Large-Scale Association Analysis Identifies New Risk Loci for Coronary Ar-tery Disease. Nature Genetics, 45, 25-33. [Google Scholar] [CrossRef] [PubMed]
[31] Erqou, S., Kaptoge, S., Perry, P.L., Di Angelantonio, E., Thompson, A., White, I.R., et al. (2009) Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality. JAMA, 302, 412-423. [Google Scholar] [CrossRef] [PubMed]
[32] Khera, A.V., Everett, B.M., Caulfield, M.P., et al. (2014) Lipoprotein (a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis from the JUPITER Trial (Justifica-tion for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation, 129, 635-642. [Google Scholar] [CrossRef] 
[33] Albers, J.J., Slee, A., O’Brien, K.D., et al. (2013) Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes: The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology, 62, 1575-1579. [Google Scholar] [CrossRef] [PubMed]

为你推荐